Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology

Volumn 17, Issue 6, 2016, Pages 822-835

  Vansteenkiste, Johan F ^a   Cho, Byoung Chul ^b   Vanakesa, Tonu ^c   De Pas, Tommaso ^d   Zielinski, Marcin ^e   Kim, Moon Soo ^f   Jassem, Jacek ^g   Yoshimura, Masahiro ^h   Dahabreh, Jubrail ⁱ   Nakayama, Haruhiku ^j   Havel, Libor ^k   Kondo, Haruhiko ^l   Mitsudomi, Tetsuya ^m   Zarogoulidis, Konstantinos ⁿ   Gladkov, Oleg A ^o   Udud, Katalin ^p   Tada, Hirohito ^q   Hoffman, Hans ^r   Bugge, Anders ^s   Taylor, Paul ^t   Gonzalez, Emilio Esteban ^u   Liao, Mei Lin ^v   He, Jianxing ^w   Pujol, Jean Louis ^x   Louahed, Jamila ^y   Debois, Muriel ^y   Brichard, Vincent ^y   Debruyne, Channa ^y   Therasse, Patrick ^y   Altorki, Nasser ^z   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Yonsei University College of Medicine   (South Korea)

^c North Estonian Regional Hospital   (Estonia)

^d Rare Tumors and Sarcomas   (Italy)

^e Department of Thoracic Surgery ^*  (Poland)

^f National Cancer Center   (South Korea)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h HYOGO CANCER CENTER   (Japan)

ⁱ ATHENS MEDICAL CENTER   (Greece)

^j KANAGAWA CANCER CENTER   (Japan)

^k CHARLES UNIVERSITY   (Czech Republic)

^l SHIZUOKA CANCER CENTER   (Japan)

^m AICHI CANCER CENTER HOSPITAL   (Japan)

ⁿ ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^o Regional Oncology Dispensary Medgorodok   (Russian Federation)

^p NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^q OSAKA CITY GENERAL HOSPITAL   (Japan)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s OSLO UNIVERSITY HOSPITAL   (Norway)

^t MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^u HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^v SHANGHAI CHEST HOSPITAL   (China)

^w GUANGZHOU MEDICAL UNIVERSITY   (China)

^x HÔPITAL ARNAUD DE VILLENEUVE   (France)

^y GSK   (Belgium)

^z WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN 3; PLACEBO; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MAGEA3 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ACUTE RESPIRATORY FAILURE; ADJUVANT THERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AORTA RUPTURE; ARTICLE; ATRIAL FIBRILLATION; ATROPHIC GASTRITIS; AUTOIMMUNE HEPATITIS; AUTOIMMUNE THYROIDITIS; BACTERIAL PNEUMONIA; BILE DUCT CARCINOMA; BLADDER CANCER; BRACHIAL PLEXUS INJURY; BRAIN ISCHEMIA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CAROTID ARTERY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CRANIAL NERVE PARALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GLOMERULONEPHRITIS; HEART ARREST; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFESTATION; LEUKOCYTOCLASTIC VASCULITIS; LUNG ALVEOLITIS; LUNG EMBOLISM; LUNG FIBROSIS; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NERVE PARALYSIS; NEURITIS; NEUROGENIC SHOCK; NON SMALL CELL LUNG CANCER; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PREDICTION; PRIORITY JOURNAL; PSORIASIS; PULMONARY ARTERY THROMBOSIS; PULMONARY ASPIRATION; PUSTULAR PSORIASIS; RADICULITIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; SEPSIS; SEVENTH NERVE PARALYSIS; SHOCK; SIDE EFFECT; SMALL CELL LUNG CANCER; SMOKING; SPONDYLOARTHROPATHY; SUDDEN DEATH; SUICIDE; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; ULCERATIVE COLITIS; URINARY TRACT INFECTION; VOCAL CORD PARALYSIS; ADJUVANT CHEMOTHERAPY; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84964637785     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00099-1     Document Type: Article

References (45)

1. 1 Ferlay, J, Steliarova-Foucher, E, Lortet-Tieulent, J, et al. Reprint of: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 51 (2015), 1201–1202.
2. 2 Vansteenkiste, J, De Ruysscher, D, Eberhardt, WE, et al., the ESMO Guidelines Working Group. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:suppl 6 (2013), vi89–vi98.
3. 3 Arriagada, R, Bergman, B, Dunant, A, Le Chevalier, T, Pignon, JP, Vansteenkiste, J, the International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004), 351–360.
4. 4 Pignon, JP, Tribodet, H, Scagliotti, GV, et al., the LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26 (2008), 3552–3559.
5. 5 Douillard, JY, Rosell, R, De Lena, M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006), 719–727.
6. 6 Kim, A, Jassem, J, Tada, H, et al. MAGE-A3 gene expression frequency and demography data of stage IB to IIIA NSCLC patients from ongoing MAGRIT phase III trial evaluating MAGE-A3 Antigen Specific Cancer Immunotherapeutic (ASCI) as adjuvant treatment. Ann Oncol, 21(suppl 8), 2010, 134.
7. 7 De Plaen, E, Arden, K, Traversari, C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40 (1994), 360–369.
8. 8 Jungbluth, AA, Busam, KJ, Kolb, D, et al. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 85 (2000), 460–465.
9. 9 Cluff, CW, Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 667 (2010), 111–123.
10. 10 Kruit, WH, Suciu, S, Dreno, B, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 31 (2013), 2413–2420.
11. 11 Vansteenkiste, J, Zielinski, M, Linder, A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 31 (2013), 2396–2403.
12. 12 Mountain, CF, Revisions in the international system for staging lung cancer. Chest 111 (1997), 1710–1717.
13. 13 Krieg, AM, Davis, HL, Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 3 (2001), 15–24.
14. 14 Meidenbauer, N, Zippelius, A, Pittet, MJ, et al. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 64 (2004), 6319–6326.
15. 15 Speiser, DE, Liénard, D, Rufer, N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 (2005), 739–746.
16. 16 Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf, Aug 9, 2006 (accessed Jan 23, 2014).
17. 17 Vantomme, V, Dantinne, C, Amrani, N, et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 27 (2004), 124–135.
18. 18 Rabin, R, de Charro, F, EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33 (2001), 337–343.
19. 19 Freidlin, B, Simon, R, Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 11 (2005), 7872–7878.
20. 20 Ulloa-Montoya, F, Louahed, J, Dizier, B, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 31 (2013), 2388–2395.
21. 21 Brookmeyer, R, Median survival time. Armitage, P, Colton, T, (eds.) Encyclopdia of biostatistics, 2005, John Wiley & Sons.
22. 22 Balch, CM, Gershenwald, JE, Soong, SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28 (2010), 2452–2459.
23. 23 Wang, SJ, O'Neill, RT, Hung, HM, Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 6 (2007), 227–244.
24. 24 Song, Y, Chi, GY, A method for testing a prespecified subgroup in clinical trials. Stat Med 26 (2007), 3535–3549.
25. 25 Spiessens, B, Debois, M, Adjusted significance levels for subgroup analyses in clinical trials. Contemp Clin Trials 31 (2010), 647–656.
26. 26 Goldstraw, P, Crowley, J, Chansky, K, et al. the International Association for the Study of Lung Cancer International Staging Committee, the Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2 (2007), 706–714.
27. 27 Strauss, GM, Herndon, JE 2nd, Maddaus, MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26 (2008), 5043–5051.
28. 28 Scagliotti, GV, Fossati, R, Torri, V, et al., the Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 95 (2003), 1453–1461.
29. 29 Olaussen, KA, Fouret, P, Kroemer, G, ERCC1-specific immunostaining in non-small-cell lung cancer. N Engl J Med 357 (2007), 1559–1561.
30. 30 Friboulet, L, Olaussen, KA, Pignon, JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368 (2013), 1101–1110.
31. 31 Bepler, G, Williams, CW, Schell, MJ, et al. Molecular analysis-directed, international, phase III trial in patients with advanced non-small-cell lung cancer. J Clin Oncol, 31(suppl), 2013 abstr 8001.
32. 32 Wislez, M, Barlesi, F, Besse, B, et al. Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. J Clin Oncol 32 (2014), 1256–1261.
33. 33 Massuti, B, Cobo, M, Rodriguez-Paniagua, JM, et al. Randomized phase III trial of customized adjuvant chemotherapy (chemotherapy) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial. Proc Am Soc Clin Oncol, 31(suppl), 2015 abstr 7507.
34. 34 Mok, TS, Wu, YL, Thongprasert, S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009), 947–957.
35. 35 Solomon, BJ, Mok, T, Kim, DW, et al., the PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
36. 36 Goss, GD, Lorimer, I, Tsao, MS, et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC chemotherapyG BR.19. Proc Am Soc Clin Oncol, 28(suppl), 2010, LBA7005.
37. 37 Kelly, K, Altorki, NK, Eberhardt, WE, et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. Proc Am Soc Clin Oncol, 32(suppl 5), 2014 abstr 7501.
38. 38 Danna, EA, Sinha, P, Gilbert, M, Clements, VK, Pulaski, BA, Ostrand-Rosenberg, S, Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64 (2004), 2205–2211.
39. 39 Atanackovic, D, Altorki, NK, Stockert, E, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172 (2004), 3289–3296.
40. 40 Pujol, JL, Vansteenkiste, JF, De Pas, TM, et al. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3-positive non-small-cell lung cancer. J Thorac Oncol 10 (2015), 1458–1467.
41. 41 Giaccone, G, Bazhenova, LA, Nemunaitis, J, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer 51 (2015), 2321–2329.
42. 42 Butts, C, Socinski, MA, Mitchell, PL, et al., the START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15 (2014), 59–68.
43. 43 Berraondo, P, Umansky, V, Melero, I, Changing the tumor microenvironment: new strategies for immunotherapy. Cancer Res 72 (2012), 5159–5164.
44. 44 Gettinger, SN, Horn, L, Gandhi, L, et al. Overall survival and long-term safety of nivolumab (anti-Programmed Death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
45. 45 Brown, SD, Warren, RL, Gibb, EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24 (2014), 743–750.